Economics
Trump Drug Plan Gains Momentum as Merck Lowers Prices
- Rebates, biosimilar competition, drug imports get priority
- President sends thanks to Norvartis and Pfizer on Twitter
This article is for subscribers only.
The Trump administration moved swiftly in the past 24 hours to implement pieces of its plan to bring down drug prices, preparing several significant steps as one of the biggest U.S. drugmakers said it would bring down the cost of some medicines.
The Health and Human Services Department on Wednesday night submitted a proposal to the White House that would curb kickback exemptions that allow drugmakers to offer insurers and pharmacy-benefit managers rebates widely blamed for keeping drug prices high. Earlier that day, the Food and Drug Administration released a plan to boost the market for so-called biosimilars, which are generic copies of expensive drugs that are made from living organisms.